About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tnfaip3tm2Ama
targeted mutation 2, Averil Ma
MGI:4831001
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Tnfaip3tm2Ama/Tnfaip3tm2Ama
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * C57BL/6 MGI:4831002
cn2
 		Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm2Ama/Tnfaip3+ 		involves: 129P2/OlaHsd * C57BL/6 MGI:4831003


Genotype
MGI:4831002
cn1
Allelic
Composition		 Tnfaip3tm2Ama/Tnfaip3tm2Ama
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (56 available)
Tnfaip3tm2Ama mutation (0 available); any Tnfaip3 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls
increased T cell number ( J:163917 )
• moderate expansion of T cells
abnormal B cell morphology ( J:163917 )
• increase in the number and size of anti-DNA producing B cells
decreased B cell number ( J:163917 )
• small decrease in the percentage of IgM+B cells in the bone marrow, reflecting a reduction in mature or recirculating B cells
increased B cell number ( J:163917 )
• moderate increase in B cells
increased plasma cell number ( J:163917 )
• increase in percentage of splenic plasma cells
abnormal B-1a B cell morphology ( J:163917 )
• percentage of B-1a cells in the peritoneal cavity is lower than in controls but the absolute numbers are not different
abnormal B cell activation ( J:163917 )
• spontaneous B cell activation becomes apparent at 6 months of age
increased B cell proliferation ( J:163917 )
• B cells are hyperresponsive to multiple stimuli
• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals
increased immunoglobulin level ( J:163917 )
• increase in glomerular immunoglobulin deposits
increased IgG level ( J:163917 )
• modest increase in IgGs
increased interleukin-6 secretion ( J:163917 )
• increase in IL-6 production by B cells after treatment with LPS and CpG
increased susceptibility to autoimmune disorder ( J:163917 )
• CpG treatment enhances production of IgG dsDNA antibodies in serum as well as deposition of IgG in renal glomeruli, indicating development of autoimmune disease
• IgM deposits are seen in the kidneys
increased autoantibody level ( J:163917 )
• mice develop autoimmunity; antibodies to over 46 self-antigens are detected, including antibodies to nuclear antigens

hematopoietic system
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls
increased T cell number ( J:163917 )
• moderate expansion of T cells
abnormal B cell morphology ( J:163917 )
• increase in the number and size of anti-DNA producing B cells
decreased B cell number ( J:163917 )
• small decrease in the percentage of IgM+B cells in the bone marrow, reflecting a reduction in mature or recirculating B cells
increased B cell number ( J:163917 )
• moderate increase in B cells
increased plasma cell number ( J:163917 )
• increase in percentage of splenic plasma cells
abnormal B-1a B cell morphology ( J:163917 )
• percentage of B-1a cells in the peritoneal cavity is lower than in controls but the absolute numbers are not different
abnormal B cell activation ( J:163917 )
• spontaneous B cell activation becomes apparent at 6 months of age
increased B cell proliferation ( J:163917 )
• B cells are hyperresponsive to multiple stimuli
• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals
increased immunoglobulin level ( J:163917 )
• increase in glomerular immunoglobulin deposits
increased IgG level ( J:163917 )
• modest increase in IgGs

cellular
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls
increased B cell proliferation ( J:163917 )
• B cells are hyperresponsive to multiple stimuli
• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals




Genotype
MGI:4831003
cn2
Allelic
Composition		 Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm2Ama/Tnfaip3+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (56 available)
Tnfaip3tm2Ama mutation (0 available); any Tnfaip3 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls
increased plasma cell number ( J:163917 )
• increase in percentage of splenic plasma cells
increased immunoglobulin level ( J:163917 )
• IgM and IgG deposits are seen in the kidneys
increased susceptibility to autoimmune disorder ( J:163917 )
• CpG treatment enhances production of IgG dsDNA antibodies in serum as well as deposition of IgG in renal glomeruli, indicating development of autoimmune disease

hematopoietic system
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls
increased plasma cell number ( J:163917 )
• increase in percentage of splenic plasma cells
increased immunoglobulin level ( J:163917 )
• IgM and IgG deposits are seen in the kidneys

cellular
decreased B cell apoptosis ( J:163917 )
• B cells are resistant to Fas-mediated programmed cell death compared to controls




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
05/07/2024
MGI 6.23 		The Jackson Laboratory